Changjiang Securities: JUMPCAN has long-term stable development, initiating a "Buy" rating

Changjiang Securities research report points out that JUMPCAN is a leading pediatric traditional Chinese medicine company with long-term stable development. The company focuses on the production and sales of medicines in pediatrics, respiratory, digestive, obstetrics and gynecology, and other fields, with main products including Pudilan Anti-inflammatory Oral Liquid and Pediatric Chiqiao Qingre Granules. In addition to its pharmaceutical business, the company's subsidiary Pudilan Daily Chemical mainly engages in daily chemical products such as Pudilan Ointment, while Kangxuyuan mainly focuses on health products. At the same time, in response to the Healthy China strategy and to accelerate the transformation and upgrading of the industry, the company has been continuously promoting the introduction of high-quality product BD since 2021, empowering external expansion through business development, which is conducive to the sustainable development of the company's business. The company's two core products have stabilized, and second-tier products are gradually gaining momentum; BD is continuously promoted, empowering long-term development. This is the first coverage, giving a "buy" rating